8H7F image
Entry Detail
PDB ID:
8H7F
Keywords:
Title:
The crystal structure of human abl1 kinase domain in complex with abl1-B-EBA
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2022-10-20
Release Date:
2023-03-01
Method Details:
Experimental Method:
Resolution:
2.45 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 2 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase ABL1
Chain IDs:A, B
Chain Length:277
Number of Molecules:2
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR A TYR modified residue
Ligand Molecules
Primary Citation
2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases.
J.Am.Chem.Soc. ? ? ? (2023)
PMID: 36774655 DOI: 10.1021/jacs.2c11595

Abstact

Lysine-targeting irreversible covalent inhibitors have attracted growing interests in recent years, especially in the fields of kinase research. Despite encouraging progress, few chemistries are available to develop inhibitors that are exclusively lysine-targeting, selective, and cell-active. We report herein a 2-ethynylbenzaldehyde (EBA)-based, lysine-targeting strategy to generate potent and selective small-molecule inhibitors of ABL kinase by selectively targeting the conserved catalytic lysine in the enzyme. We showed the resulting compounds were cell-active, capable of covalently engaging endogenous ABL kinase in K562 cells with long-residence time and few off-targets. We further validated the generality of this strategy by developing EBA-based irreversible inhibitors against EGFR (a kinase) and Mcl-1 (a nonkinase) that covalently reacted with the catalytic and noncatalytic lysine within each target.

Legend

Protein

Chemical

Disease

Primary Citation of related structures